Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Tarsus Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Tarsus Pharmaceuticals's price to sales ratio was 5.5× on Nov 11, 2026, against 9.3× a year earlier. Over the last 5 years it ranged from 4.7× to 74.9×, with a median of 12.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.5× | −4.0 |
| 2025 | Dec 31, 2025 | 9.5× | −6.8 |
| 2024 | Dec 31, 2024 | 16.3× | −30.3 |
| 2023 | Dec 29, 2023 | 46.6× | +22.4 |
| 2022 | Dec 30, 2022 | 24.2× | +16.0 |
| 2021 | Dec 31, 2021 | 8.2× | – |
See a number that looks wrong?